NasdaqGS - Delayed Quote USD

Bolt Biotherapeutics, Inc. (BOLT)

1.1100 0.0000 (0.00%)
At close: April 23 at 4:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
7,876.0000
7,876.0000
5,729.0000
1,260.0000
231.0000
Operating Expense
84,072.0000
84,072.0000
96,050.0000
94,048.0000
49,413.0000
Operating Income
-76,196.0000
-76,196.0000
-90,321.0000
-92,788.0000
-49,182.0000
Net Non Operating Interest Income Expense
6,999.0000
6,999.0000
2,223.0000
281.0000
199.0000
Other Income Expense
--
--
--
-6,084.0000
-11,745.0000
Pretax Income
-69,197.0000
-69,197.0000
-88,098.0000
-98,591.0000
-60,728.0000
Net Income Common Stockholders
-69,197.0000
-69,197.0000
-88,098.0000
-98,591.0000
-60,728.0000
Diluted NI Available to Com Stockholders
-69,197.0000
-69,197.0000
-88,098.0000
-98,591.0000
-60,728.0000
Basic EPS
-1.83
--
-2.36
-2.97
-1.91
Diluted EPS
-1.83
--
-2.36
-2.97
-1.91
Basic Average Shares
37,811.9840
--
37,358.4250
33,196.7120
31,846.6980
Diluted Average Shares
37,811.9840
--
37,358.4250
33,196.7120
31,846.6980
Total Operating Income as Reported
-76,196.0000
-76,196.0000
-90,321.0000
-92,788.0000
-49,182.0000
Total Expenses
84,072.0000
84,072.0000
96,050.0000
94,048.0000
49,413.0000
Net Income from Continuing & Discontinued Operation
-69,197.0000
-69,197.0000
-88,098.0000
-98,591.0000
-60,728.0000
Normalized Income
-69,197.0000
-69,197.0000
-88,098.0000
-92,507.0000
-48,983.0000
Interest Income
6,999.0000
6,999.0000
2,223.0000
281.0000
199.0000
Net Interest Income
6,999.0000
6,999.0000
2,223.0000
281.0000
199.0000
EBIT
-76,196.0000
-76,196.0000
-90,321.0000
-92,788.0000
-49,182.0000
EBITDA
-74,342.0000
-74,342.0000
-88,655.0000
-91,595.0000
-48,571.0000
Reconciled Depreciation
1,854.0000
1,854.0000
1,666.0000
1,193.0000
611.0000
Net Income from Continuing Operation Net Minority Interest
-69,197.0000
-69,197.0000
-88,098.0000
-98,591.0000
-60,728.0000
Total Unusual Items Excluding Goodwill
--
--
--
-6,084.0000
-11,745.0000
Total Unusual Items
--
--
--
-6,084.0000
-11,745.0000
Normalized EBITDA
-74,342.0000
-74,342.0000
-88,655.0000
-85,511.0000
-36,826.0000
12/31/2020 - 2/5/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ACHL Achilles Therapeutics plc
0.7811
-2.24%
 
NXTC NextCure, Inc.
1.5300
-4.97%
 
BCAB BioAtla, Inc.
2.2400
+2.75%
 
ATHA Athira Pharma, Inc.
2.0400
-2.39%
 
ALGS Aligos Therapeutics, Inc.
0.8236
+2.82%
 
MRSN Mersana Therapeutics, Inc.
3.2100
+1.90%
 
SNSE Sensei Biotherapeutics, Inc.
0.9977
+7.18%
 
CMPX Compass Therapeutics, Inc.
1.5200
+2.01%
 
PMVP PMV Pharmaceuticals, Inc.
1.8050
+4.34%
 
KZR Kezar Life Sciences, Inc.
0.8260
+0.49%